INVIVO III/ Thrilled to announce we are preparing the closing of III fund, aiming for €100-120M (cell & gene therapy + synthetic biology + AI). Laura Rodríguez is now Partner. Having Laura is a privilege; she stands out as one of the most talented individuals I have ever encountered.

PODCAST/ Here’s my conversation with Christian Christian Soschner where we talk about AI, Synbio, Art, and the Future of Mankind. Below is the original post from Christian with the full video (a little over 2 hours). CLICK HERE TO WATCH THE EPISODE: lnkd.in/e6_74SgK

Sam Altman: “Hire for values first, aptitude second, and skills third.” Most executive recruiters, Sam argues, will reverse this order: “If you say I need to hire a CFO, they will bring you people with 20 years of experience as a CFO at vaguely similar companies. But

Lovely summary by Drs Luis Pareras and Cinta Díez at Invivo Partners in interesting strategies to bypass T cell dysfunction!!! Just amplifying their ideas/concepts of interest!!!

Engaging discussion on challenges, trends, and value drivers shaping the C&GT space, and the potential growth opportunities in Europe at #ATE24 At Invivo Partners , we believe the C&GT field will advance into new indications, novel cell types, and cutting-edge technologies.

🏥🚀 Vine a les jornades del #CampusClínicInnova 2024 on ponents destacats parlaran sobre innnovació en salut: ✔️ Disseny de sistemes de simulació en salut ✔️ Teràpies avançades ✔️ El futur de la medicina ✔️ IA en transformació digital Inscriu-t'hi 👉 i.mtr.cool/tymggnnbgb

PORTFOLIO NEWS/ I’m proud to announce the first investment from our new fund, Invivo Ventures III. Neumirna Tx has secured a €20M Series A, led by Invivo Partners and Angelini Ventures (corporate arm of Angelini Pharma), to develop RNA-based therapies for drug-resistant epilepsy

THE INSIDE STORY OF AN INVESTMENT/ We are proud to announce that our portfolio company ESOBIOTEC is to be acquired by ASTRAZENECA in a landmark early-stage deal totaling $1B ($425M upfront), only 16 months after our investment. Read here: linkedin.com/posts/lluispar…